Novo’s Insulin Icodec Hypoglycemia Risk Outweighs Limited Benefit In Type 1 Diabetes–FDA Panel

 
• By Sue Sutter
Scales
The risks of insulin icodec outweigh its benefits in type 1 diabetes, the adcomm said. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers